BridgeBio Pharma (NASDAQ:BBIO) Given New $95.00 Price Target at Truist Financial

BridgeBio Pharma (NASDAQ:BBIO) had its price objective upped by Truist Financial from $86.00 to $95.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued reports about the company. Oppenheimer raised their price objective on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Morgan Stanley boosted their price target on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a research note on Wednesday. Sanford C. Bernstein assumed coverage on shares of BridgeBio Pharma in a report on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price objective on the stock. Piper Sandler lifted their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Finally, Leerink Partners boosted their target price on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $82.50.

BridgeBio Pharma Stock Performance

BBIO stock opened at $66.54 on Wednesday. BridgeBio Pharma has a one year low of $28.33 and a one year high of $84.94. The firm has a market cap of $12.82 billion, a PE ratio of -17.60 and a beta of 1.13. The firm’s 50 day moving average price is $75.09 and its 200-day moving average price is $64.54.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. During the same period last year, the firm earned ($1.40) EPS. The business’s revenue for the quarter was up 2521.2% compared to the same quarter last year. Equities research analysts predict that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In related news, CEO Neil Kumar sold 28,053 shares of BridgeBio Pharma stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $71.39, for a total value of $2,002,703.67. Following the completion of the transaction, the chief executive officer directly owned 234,451 shares in the company, valued at approximately $16,737,456.89. This trade represents a 10.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Maricel Apuli sold 510 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total value of $37,898.10. Following the transaction, the chief accounting officer directly owned 123,945 shares of the company’s stock, valued at $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 204,174 shares of company stock valued at $15,012,335 in the last quarter. Corporate insiders own 18.20% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of BridgeBio Pharma during the second quarter worth approximately $25,000. Aster Capital Management DIFC Ltd purchased a new position in BridgeBio Pharma in the third quarter worth approximately $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma during the 3rd quarter worth approximately $34,000. Jones Financial Companies Lllp purchased a new stake in shares of BridgeBio Pharma in the 1st quarter valued at approximately $35,000. Finally, First Horizon Corp purchased a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Q4 revenue beat and commercial update — BridgeBio reported $154.2M in Q4 revenue (well above estimates) and provided commercial progress on Attruby, which supports the company’s path to commercialization and helped lift sentiment. BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
• Positive Sentiment: Multiple analyst price-target increases — Morgan Stanley, Truist and other firms raised targets (Morgan Stanley to $98, Truist to $95 and others higher), signaling continued analyst confidence and providing upside thesis for longer-term holders. Analyst Coverage
• Neutral Sentiment: Conference call / transcripts available — The full earnings call and transcripts are published for investors to parse forward guidance and commercial cadence; further detail could move the stock once digested. Listen to Conference Call
• Neutral Sentiment: Short-interest report appears irregular — the February short-interest entry shows 0 shares / NaN change, likely a reporting glitch; this makes short-interest an unreliable read today. (No reliable source link provided in the alert.)
• Negative Sentiment: EPS missed expectations — BridgeBio reported a $1.00 loss per share vs. the consensus -$0.75, a larger-than-expected loss that is pressuring the stock despite the revenue beat. Zacks: Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Insider selling by CEO — CEO Neil Kumar sold ~28k shares (part of a pattern of recent sales), which can be interpreted negatively by some investors as liquidity-taking by management. InsiderTrades: Neil Kumar Sells Shares
• Negative Sentiment: One analyst trimmed target slightly — Oppenheimer lowered its target to $81 (still an outperform), introducing a modest counterpoint to the otherwise bullish analyst activity. Benzinga: Oppenheimer Price Target Change

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.